Company Encyclopedia
View More
name
Biotron Limited
BIT.AU
News
View More

Biotron Limited Announces Investor Webinar on Sedarex Acquisition

Biotron Limited (AU:BIT) has announced an investor webinar on November 11, 2025, where Managing Director Michelle Miller will discuss the acquisition of Sedarex Limited. This strategic acquisition aims to enhance Biotron's industry position by expanding its portfolio and potentially increasing market share, which may significantly impact stakeholders. Biotron focuses on developing novel antiviral therapies for viral diseases, with a current market cap of A$6.11M.

Tip Ranks·
Tip Ranks·

Biotron Limited Appoints Michael Medway as Non-Executive Director

Biotron Limited has appointed Michael Medway as a Non-Executive Director, effective immediately. With over 30 years of experience in the professional accounting industry, Medway's expertise is expected to enhance Biotron’s strategic direction and governance. The company focuses on developing antiviral therapies and aims to address unmet medical needs in the biotechnology sector. Current market cap stands at A$2.65M.

Tip Ranks·
Tip Ranks·

Biotron Limited Delays Rights Issue Opening Amid ASIC Queries

Biotron Limited has announced a delay in the opening of its rights issue due to queries from the Australian Securities and Investments Commission (ASIC). The new opening date is set for 17 March 2025, with further details to be confirmed. This delay may affect the company's fundraising efforts and operational plans. Biotron operates in the biotechnology sector, focusing on antiviral therapies. Current market cap is $4.54M, with a year-to-date price performance of 390.0%.

Tip Ranks·
Tip Ranks·

Biotron Limited Partners with C14 Consulting to Advance Antiviral Programs

Biotron Limited has partnered with C14 Consulting Group LLC to enhance its antiviral programs, including its lead asset BIT225. This collaboration aims to refine Biotron's commercialization strategy, leveraging C14's expertise in the pharmaceutical sector. The company is focused on achieving commercial outcomes from its antiviral programs, supported by data from three Phase 2 clinical trials. Biotron is also advancing its anti-HBV compounds and has disclosed financial expenditures on research and development. The company operates in the pharmaceutical industry, targeting various viruses with its product portfolio.

Tip Ranks·
Tip Ranks·